Menu Search
Equities

KeyMed Biosciences Inc

2162:HKG.HS

KeyMed Biosciences Inc

Actions
  • Price (HKD)37.65
  • Today's Change-0.40 / -1.05%
  • Shares traded837.50k
  • 1 Year change-36.51%
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Keymed Biosciences Inc is a China-based biotechnology company. The Company focuses on the independent discovery and development of innovative biological therapies that address underserved medical needs in the autoimmune and oncology therapeutic areas. The Company has mastered in-house drug discovery and development technologies, including an innovative antibody discovery platform and a proprietary novel T cell engager (nTCE) bispecific antibody platform. The Company has also established a fully integrated platform covering the key functions of biopharmaceutical development. The Company's main products include CM310, CM326 and CMG901.

  • Revenue in HKD (TTM)382.70m
  • Net income in HKD-388.39m
  • Incorporated2018
  • Employees897.00
  • Location
    KeyMed Biosciences Inc18 Biotown Middle Road Building D2Chengdu Tianfu International BiotownCHENGDU 610219ChinaCHN
  • Websitehttps://www.keymedbio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.